Signs Western companies are turning to China for cancer innovation

In the latest sign of China biotech’s maturation, the last two years have seen Chinese companies out-license a dozen innovative cancer therapies to Western players. Only five of these products are small molecules or standard mAbs, and seven do not share a target with an FDA-approved drug, according to BioCentury’s BCIQ database.

The analysis indicates the days of cross-border deals going only one direction — China biotechs tapping the West for innovation — are gone. ...